Novavax has shared positive preliminary results from a real-world study of its JN.1-adapted COVID-19 vaccine. The SHIELD-Utah ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Health secretary Robert F. Kennedy Jr. has expressed another unorthodox view on vaccines, declaring that single antigen ...

Shares of Novavax, Inc. (NVAX) plunged over 19.5% on Thursday after Health and Human Services Secretary Robert F. Kennedy Jr.

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services Secretary ...

As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly ...

Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...

Novavax, the little-known Maryland company that received a $1.6 billion deal from the federal government for its experimental coronavirus vaccine, announced encouraging results in two preliminary ...

Novavax (NasdaqGS:NVAX) recently announced promising preliminary results from the SHIELD-Utah study, which highlighted fewer and less severe reactogenicity symptoms for its COVID-19 Vaccine, ...

Novavax (NasdaqGS:NVAX) experienced a noteworthy 13% increase in its share price last week, coinciding with significant changes in its leadership. The retirement of James Young as Chair of the Board ...

Shares of Novavax Inc. NVAX shed 2.97% to $6.20 Wednesday, on what proved to be an all-around dismal trading session for the ...